2018年

by 腫瘍病態学分野
  1. Natsumeda M, Igarashi H, Motohashi K, Suzuki Y, Ohkubo M, Okamoto K, Watanabe M, Nakada T, Fujii Y. Advances and challenges in assessing 2-hydroxyglutarate in gliomas by magnetic resonance spectroscopy: a short review. Neuropsychiatry (London), 8(6): 1831-1838, 2018.
  2. Abe H, Natsumeda M, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Yoshimura J, Oishi M, Fujii Y. MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas and MGMT silencing to temozolomide sensitivity in IDH-mutant gliomas. Neurol Med Chir (Tokyo), 58(7):290-295, 2018.
  3. Natsumeda M, Uzuka T, Watanabe J, Fukuda M, Akaiwa Y, Hanzawa K, Okada M, Oishi M, Fujii Y. High incidence of deep vein thrombosis in the perioperative period of neurosurgical patients. World Neurosurg, 112:e103-e112, 2018. 
  4. Natsumeda M, Motohashi K, Igarashi H, Nozawa T, Abe H, Tsukamoto Y, Ogura R, Okada M, Kobayashi T, Aoki H, Takahashi H, Kakita A, Okamoto K, Nakada T, Fujii Y. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-tesla magnetic resonance spectroscopy. Neurosurg Rev, 41(2):642-647, 2018.